At the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, PicnicHealth data was featured in two posters presented by our research partners. Continue reading below for more information on how your contribution is supporting leading Multiple Sclerosis researchers.
Multiple Sclerosis and COVID-19
Research Partners: Roche / Genentech
This study aimed to describe the COVID-19 vaccination patterns and COVID-19 outcomes among patients with multiple sclerosis (pwMS) in the FlywheelMS cohort and within subgroups of pwMS defined by their most recent disease-modifying therapy (DMT) status.
Why is it important?
Vaccination against SARS-CoV-2 is recommended for all pwMS to prevent severe COVID-19 infection and death, but there has been limited research into the COVID-19 outcomes in this population that maybe have impaired immune responses due to receiving immunosuppressive therapies to treat their MS.
This study used a new feature within the PicnicHealth Patient app to deliver in-app surveys to ask participants about their COVID-19 vaccination history and store their vaccination cards.
Looking at 1151 pwMS, 80% of patients were fully vaccinated or boosted, and among those fully vaccinated, 75% had received at least 1 booster or additional dose.
While this was a small study, the rate of vaccination in this population of pwMS was higher than that seen in the general US population and the rate of serious breakthrough infections was low.
Within this population of pwMS the rate of vaccination was higher among pwMS with known risk factors for severe COVID-19 outcomes, including older individuals, males, and those currently treated with immunosuppressive drugs.
Poster 1. Geiger C, Sheinson D, Boudreau D, Mace K, Hanson G, Belendiuk K, Bajaj P, COVID-19 vaccination patterns and outcomes among persons with multiple sclerosis in the FlywheelMS cohort, ECTRIMS 2022 - ePoster. Multiple Sclerosis journal 2022;28(3_suppl):692-945.
Ongoing Observational Multiple Sclerosis Study
Research partners: Atara Biotherapeutics
PicnicHealth has developed a novel real-world data, medical records-based research cohort to study multiple sclerosis. This poster provides the initial study design, patient demographics and description of the healthcare resources utilization of patients with active and nonactive progressive multiple sclerosis (PMS).
Why is this important?
Multiple sclerosis is commonly characterized broadly as either a primarily relapsing or progressive disease course. Despite differences in outcomes for patients with relapsing MS and PMS, there is only one diagnosis code used in real-world clinical care for MS, which does not distinguish between these two disease courses. This code also does not reflect patient’s disease activity (active vs. nonactive). As a result, there is limited real-world data available to better understand PMS.
Of the patients with PMS enrolled in this study, the majority of participants had nonactive PMS, meaning they were not experiencing relapses recently and did not have recent evidence of new activity on an MRI.
Examining approximately 5 years of available visit data, 45% of participants experienced at least 1 hospitalization and, for those hospitalizations, the median length of stay in the hospital was 4 days.
This is an ongoing, patient-centered study where robust real-world data can be used to generate meaningful future insights.
Poster 2. Watson C, Sadetsky N, Xun P, Thirumalai D, Colbert-Pollack S, Friedler H, Liebes G, Bogdanovich S, Kresa-Reahl K, Hanson G, Barlev A, A novel, patient-centred real-world evidence study designed to better understand active and non-active progressive multiple sclerosis using health records in the United States, ECTRIMS 2022 - ePoster. Multiple Sclerosis journal 2022;28(3_suppl):692-945.